Rani Therapeutics Holdings, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs through its proprietary RaniPill® capsule platform. The RANI news page on Stock Titan aggregates company press releases, market announcements and regulatory updates so readers can follow how this oral biologics platform is progressing through preclinical and clinical development.

According to the company’s disclosures, recent news has highlighted pipeline milestones, such as preclinical data and the initiation of a Phase 1 clinical trial for RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist (PG-102) being developed for the treatment of obesity. Rani has also reported preclinical data on oral semaglutide (RT-116) and on oral delivery of a bispecific GLP-1/GLP-2 receptor agonist via RaniPill, with results described as comparable in bioavailability and weight loss to subcutaneous injections in animal models.

Investors and observers can use this news feed to track strategic collaborations and financings, including Rani’s Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. for an oral product combining RaniPill HC with a rare disease antibody, and its collaboration with ProGen Co., Ltd. for RT-114 in weight management. The company’s announcements also cover private placements, registered offerings, warrant transactions and related board changes tied to institutional investors.

In addition, Rani’s news includes quarterly financial results and corporate updates, where management discusses cash runway expectations, research and development spending and progress across its oral biologics pipeline. For anyone following RANI stock or the evolution of oral delivery technologies for biologics, this page offers a centralized view of company-generated news, from clinical trial plans to collaboration agreements and capital markets activity.